Application of polyiodobenzoic acid as cvb3 virus inhibitor

A technology of iodobenzoic acid and diiodobenzoic acid, which is applied in antiviral agents, active ingredients of salicylic acid, medical preparations containing active ingredients, etc., can solve the problems of unreported inhibitory activity and achieve enhanced cell survival High rate, high therapeutic index, good anti-CVB3 virus effect

Active Publication Date: 2021-08-17
HUBEI UNIV OF TECH
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the antiviral activity of iodocarboxylic acids, including the inhibitory activity against CVB3 virus, has not been reported so far.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polyiodobenzoic acid as cvb3 virus inhibitor
  • Application of polyiodobenzoic acid as cvb3 virus inhibitor
  • Application of polyiodobenzoic acid as cvb3 virus inhibitor

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0027] Embodiment 1: polyiodobenzoic acid L 6 , L 7 Toxicity to host Hep-2 cells

[0028] Hep-2 cells were plated in 96-well plates at 37°C, 5% CO 2 After the incubator grows a monolayer, discard the cell culture medium and add different concentrations of L 6 , L 7 After 48 hours, the cytotoxicity was recorded under a microscope, and the cell viability was measured by MTT method. The specific steps of the MTT method are as follows: add 30 μL of MTT (5 mg·mL -1 ), after incubation for 3-4 h, the supernatant was removed, and 50 μL of DMSO was added to dissolve the precipitate. Read the corresponding absorbance (OD) at 492 nm with a microplate reader 492 value).

[0029] SPSS 11.5 software was used to calculate the median toxic concentration (Medencyctoxic concentration, CC50) of the drug on the cells.

[0030] Cell viability=(average OD of drug group 492 Value / average OD of cell control group 492 value)×100%

Embodiment 2

[0031] Embodiment 2: polyiodobenzoic acid L 6 , L 7 Inhibitory activity against CVB3

[0032] Hep-2 cells were plated in 96-well plates at 37°C, 5% CO 2 After the monolayer was grown in the incubator, discard the culture medium, infect the cells with 100TCID50 CVB3 virus solution for 1h, and add different concentrations (2.5μg / mL, 5μg / mL, 10μg / mL, 20μg / mL, 40μg / mL, 80μg / mL) of compound L 6 , L 7 (ribavirin as a positive control drug) to incubate the cells. After continuing to culture for about 48 hours, when about 90% of the CPE lesions appeared in the virus control wells, the cytopathic effect (CPE) was observed under a microscope. Observation and recording method of CPE: No cytopathic disease is marked as -, cytopathic disease of less than 25% is recorded as +, 25%-50% cytopathic disease is recorded as ++, 50%-75% cytopathic disease is recorded as +++, more than 75% Cytopathy was recorded as ++++.

[0033] After the observation of CPE, the inhibitory rate of drugs on...

Embodiment 3

[0045] Embodiment 3: polyiodobenzoic acid L 6 , L 7 Inhibition of CVB3 Progeny Virus Yield

[0046] Hep-2 cells in the logarithmic growth phase were plated in 24-well plates, and 100TCID after the monolayer was overgrown 50 CVB3 infected cells, incubated at 37°C for 1.5h, removed the virus solution, washed three times with PBS, and added cell maintenance solution containing 25 μg / mL L6 and 50 μg / mL L7 respectively. Cells and supernatant culture fluid were collected at 12h and 36h respectively, and after three freeze-thaw lysis at -20°C and 37°C, TCID 50 Methods To determine the titer of CVB3 virus.

[0047] The result is as image 3 As shown, the CVB3 virus control group showed obvious virus titers at 12 hours after infection, and the virus titers rose rapidly by about 3.0log until 36 hours after infection. However, the virus titers of the 25 μg / mL L6 and 50 μg / mL7 treatment groups were lower than those of the virus control group under the same time conditions, and the i...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses the application of polyiodobenzoic acid as a CVB3 virus inhibitor. Through the research on the anti-CVB3 activity of several polyiodobenzoic acids, it was shown that the polyiodobenzoic acids exhibited certain inhibitory activity on CVB3 virus, including inhibiting the cytopathic effect (CPE) produced by CVB3 on the host cell Hep-2 , enhance cell viability, polyiodobenzoic acid has inhibitory effect on CVB3 virus, indicating that polyiodobenzoic acid has the potential to be used in the preparation of anti-CVB3 virus drugs.

Description

technical field [0001] The invention relates to the technical field of antiviral drugs, in particular to the application of polyiodobenzoic acid as a CVB3 inhibitor. Background technique [0002] Coxsackievirus (CV) is a member of Picornaviridae Enterovirus, its infection can cause a variety of diseases, such as hand, foot and mouth disease, aseptic meningitis, encephalitis, myocarditis , epidemic myositis, herpetic angina, etc. There are 29 serotypes of CV reported, which can be divided into two groups, A and B, according to their pathogenic characteristics and cell sensitivity to suckling mice, namely CVA (CVA1-22, 24) and CVB ( CVB1-6). CVBs infection is the most common, among which CVB3 is the most pathogenic type among the six CVB serotypes, and is the main cause of viral myocarditis. According to the statistics of the US Centers for Disease Control and Prevention (CDC), CVB (type 1-6) can cause about 5 million people to suffer from intestinal system diseases every y...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/60A61P31/14A61K31/7056
CPCA61K31/60A61K31/7056A61P31/14A61K2300/00
Inventor 王龙胜郭超魏艳红李妮朱茂春王悦袁子月吴忠家
Owner HUBEI UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap